{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:05:26Z","timestamp":1784264726550,"version":"3.55.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background\/objective<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell therapy has been the standard of care for relapsed\/refractory B-cell lymphomas (r\/r BCLs) in recent years. However, high cost of commercial products limits their application in real-world clinical practice. The use of the so-called academic CAR-T cell products can reduce the cost and improve availability and affordability of this therapy option. The aim of the present clinical trial was to assess the efficacy and safety of academic CAR-T cells in r\/r BCL patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>From June 2021 to December 2025, this prospective clinical trial enrolled 76 r\/r BCL patients treated at the N.N. Alexandrov National Cancer Centre of Belarus (Minsk, Republic of Belarus), ClinicalTrials.gov Identifier: NCT07524816. The patients were 23\u201368 years of age (median 47 years). The CAR-T cell product was manufactured using lentiviral vector encoding anti-CD19 CAR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median follow-up was 7.85 months for the entire cohort and 20.12 months for patients without events. Generally, complete response was achieved in 57.5% of patients. The 4-year event-free survival (EFS) rate was 46.2 \u00b1 6.3%, and the 4-year overall survival (OS) rate was 67 \u00b1 5.9%. Among patients with follicular lymphoma (FL), complete response was achieved in 83.3% patients. The 4-year EFS was 81.7 \u00b1 9.6%. The safety profile was acceptable: cytokine release syndrome (CRS) was detected in 43.4% of patients (\u2265 grade 3 in 2.6%). No cases of grade 4 CRS were reported, and neurotoxicity (ICANS) was identified in 26.3% of patients (\u2265 grade 3 in 5.3%, grade 4 ICANS occurred in two patients \u2013 2.6%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The anti-CD19 CAR T-cell product demonstrates good efficacy and acceptable toxicity in patients with r\/r BCL. The use of such a product is the only available option for patients in countries where commercial products are not accessible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/clinicaltrials.gov\/study\/NCT07524816<\/jats:uri>\n                      , identifier NCT07524816.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1862517","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:22:52Z","timestamp":1784262172000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Academic anti CD19 CAR-T cell therapy for relapsed\/refractory B-cell lymphomas in real-world clinical practice: a prospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Natalya E.","family":"Konoplya","sequence":"first","affiliation":[{"name":"N. N. Alexandrov National Cancer Centre of Belarus","place":["Minsk, Belarus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana M.","family":"Doroshenko","sequence":"additional","affiliation":[{"name":"N. N. Alexandrov National Cancer Centre of Belarus","place":["Minsk, Belarus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsiaryna Yu.","family":"Zharkova","sequence":"additional","affiliation":[{"name":"N. N. Alexandrov National Cancer Centre of Belarus","place":["Minsk, Belarus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana V.","family":"Savich","sequence":"additional","affiliation":[{"name":"N. N. Alexandrov National Cancer Centre of Belarus","place":["Minsk, Belarus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihar M.","family":"Seviaryn","sequence":"additional","affiliation":[{"name":"N. N. Alexandrov National Cancer Centre of Belarus","place":["Minsk, Belarus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadezhda M.","family":"Bobrova","sequence":"additional","affiliation":[{"name":"N. N. Alexandrov National Cancer Centre of Belarus","place":["Minsk, Belarus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey A.","family":"Beleevsky","sequence":"additional","affiliation":[{"name":"N. N. Alexandrov National Cancer Centre of Belarus","place":["Minsk, Belarus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldar Kh.","family":"Sarydze","sequence":"additional","affiliation":[{"name":"N. N. Alexandrov National Cancer Centre of Belarus","place":["Minsk, Belarus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey L.","family":"Polyakov","sequence":"additional","affiliation":[{"name":"N. N. Alexandrov National Cancer Centre of Belarus","place":["Minsk, Belarus"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148948","article-title":"Two-year follow-up of transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R\/R) large B-cell lymphomas (LBCL)","volume":"138","author":"Abramson","year":"2021","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018893","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02444-x","article-title":"Cost-effectiveness of lisocabtagene maraleucel versus axicabtagene ciloleucel and tisagenlecleucel in the third-line or later treatment setting for relapsed or refractory large B-cell lymphoma in the United States","volume":"40","author":"Parker","year":"2023","journal-title":"Adv Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00482","article-title":"Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: experience from an academic phase I clinical trial","volume":"11","author":"Castella","year":"2020","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.228577","article-title":"Preclinical development of a humanized chimeric antigen receptor against B-cell maturation antigen for multiple myeloma","volume":"106","author":"Perez-Amill","year":"2021","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.09.027","article-title":"CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19+ relapsed\/refractory Malignancies","volume":"29","author":"Ort\u00edz-Maldonado","year":"2021","journal-title":"Mol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00222-X","article-title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMAdirected CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study","volume":"8","author":"Oliver-Cald\u00e9s","year":"2023","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03035-1","article-title":"Enhancing pediatric access to cell and gene therapies","volume":"30","author":"Mackall","year":"2024","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.33696\/immunology.6.204","article-title":"Clinical case report of CAR-T therapy of patient with refractory burkitt's lymphoma","volume":"6","author":"Doroshenko","year":"2024","journal-title":"J Cell Immunol"},{"key":"B16","unstructured":"Guidelines Version 2.2025. B-Cell Lymphomas"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41408-025-01225-9","article-title":"Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel","volume":"15","author":"Dulobdas","year":"2025","journal-title":"Blood Cancer J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma [published correction appears in Blood Adv. 2021;5(4):1136","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2025.04.067","article-title":"Clinical outcomes of Japanese patients treated with out-of-specification tisagenlecleucel in a phase 3b trial","volume":"27","author":"Kato","year":"2025","journal-title":"Cytotherapy"},{"key":"B26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-026-02923-z","article-title":"Access to CAR-T cell therapy in Central and Eastern Europe: persistent barriers and inequalities as of October\/November 2025","author":"Liszka","year":"2026","journal-title":"Bone Marrow Transplant"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1862517\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:22:53Z","timestamp":1784262173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1862517\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":27,"alternative-id":["10.3389\/fonc.2026.1862517"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1862517","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"article-number":"1862517"}}